Pharma Solutions

Supported by science

Omega-3 fatty acids EPA and DHA are investigated in clinical science for wide range of health conditions. Currently major therapeutic application of EPA and DHA is in CVD and refers to lowering plasma triglyceride levels.  Backed by extensive scientific evidence, EPA and DHA provide vital support to heart health in pharmaceutical applications, lowering plasma triglycerides levels, decreasing resting heart rate, blood pressure and inflammation, and improving vascular function.

Clinical trials referring to DHA and EPA cover such conditions as rheumatoid arthritis, osteoporosis, stroke, traumatic brain injury, cognitive decline, Alzheimer’s disease, depression, attention deficit/hyperactivity disorder, macular degeneration, asthma, inflammatory bowel disease, colon/breast/prostate cancer, skin disorders, sarcopenia, post-surgical recovery and others.

Contact us to find out more about our broad spectrum of EPA and DHA ingredients. 

February 2, 2018
Long-Chain n-3 Fatty Acids and Cancer Risk: What’s the Prognosis? READ MORE
December 1, 2017
Understanding Drug Nutrient Interactions READ MORE
November 14, 2017
DSM speaks at Nicholas Hall OTC Conference READ MORE
October 25, 2017
The Roles of Lipids in the Most Recent History of Cancer Prevention READ MORE
October 24, 2017
The Effect of Vitamin E on Cardiovascular Risk Reduction READ MORE
September 18, 2017
DSM Brings New Innovative Therapeutic Concepts to CPHI 2017 READ MORE